WP Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

WP Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-650	Closed	-$226	–	174
2019 Q1	$226	Buy	+650	New	+$18.8K	0.02%	166
2018 Q4	–	Sell	-650	Closed	-$17K	–	258
2018 Q3	$17K	Hold	650	–	–	0.02%	194
2018 Q2	$25K	Buy	+650	New	+$24.9K	0.02%	176

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

WP Advisors's PTLA Position: Q2 2019 in Review

WP Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 650 shares — an estimated $226 sold.

WP Advisors first reported a position in PTLA in Q2 2018 and held it in 3 quarters. The position peaked at $25K in Q2 2018. 201 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

WP Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
WP Advisors sold 650 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $226.
WP Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
WP Advisors's Portola Pharmaceuticals, Inc. position peaked at $25K in Q2 2018.
201 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on WP Advisors's 13F filing for Q2 2019, filed 23 Jul 2019.